NCT00609401View on ClinicalTrials.gov

Study Comparing Association Between Sorafenib and Interleukin-2 (IL-2) Versus Sorafenib in 1st Line Therapy in Advanced (Adv) Renal Cell Carcinoma (RCC)

PHASE2CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

May 31, 2007

Study Completion Date

May 31, 2008

Conditions
Metastatic DiseaseRenal Cell Carcinoma
Interventions
DRUG

Nexavar (Sorafenib)

400 mg bid

DRUG

IL-2

IL-2 3 MU per 5 day/week for 2 weeks every 4

Trial Locations (1)

Unknown

Istituto Tumori, Milan

All Listed Sponsors
lead

Italian Trial in Medical Oncology

OTHER

NCT00609401 - Study Comparing Association Between Sorafenib and Interleukin-2 (IL-2) Versus Sorafenib in 1st Line Therapy in Advanced (Adv) Renal Cell Carcinoma (RCC) | Biotech Hunter | Biotech Hunter